FDA warns BD over blood collection tubes used in Magellan’s lead testing kit

The FDA issued a warning letter to Becton Dickinson & Co. (NYSE:BDX) today, citing a number of violations of federal law that it identified in an inspection of the company’s New Jersey facility. The inspection, which was done as part of the agency’s ongoing investigation into the cause of inaccurate blood lead tests linked to Magellen […]

BD closes $24B Bard buy-out

Becton Dickinson & Co. (NYSE:BDX) said today that it completed its buy-out of C.R. Bard (NYSE:BCR). The combined company boasts $16 million in yearly revenue. The $317-per-share deal was first announced in April and in the past few months won conditional approval in the E.U., the U.S. and China. “Today is a historic day for BD as […]

Here are the top 5 medtech stories of mid-2017

The middle of 2017 is shaping up to be a continued whirlwind of activity for medtech. FDA is getting used to its new leadership but is facing a continued lack of clarity on user fees and UDIs. Industry is seeing a deeper consolidation in medical supplies, exemplified in Cardinal Health’s purchase of patient recovery supplies from

Pages: 1 2 3 4 5 6

Superbugs: Diagnostic test makers think they have an answer

Becton Dickinson and other diagnostic test makers have launched a global push to promote more testing, in the hopes of identifying antibiotic-resistant superbugs before they become a serious problem. AdvaMedDx, a group that represents diagnostic test manufacturers, announced the initiative on Friday in collaboration with the Joint United Nations Program on HIV/AIDs at the World Economic Forum